|
Marcus' Biotech Briefing
Puerto Rico is pitching itself as a biotech manufacturing base, while iBio and Actio Biosciences advance AI-driven discovery and precision medicine programs into the clinic.
The top 10 stories from Thu Jun 25, 2026 06:50 AM to Fri Jun 26, 2026 06:51 AM
Generated June 26, 2026 at 6:51 AM
|
|
|
#1 NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease Published 2026-06-25 NeuroSense reported positive Phase 2 RoAD proof-of-concept biomarker results for PrimeC in Alzheimer’s, showing changes across multiple neurodegenerative disease pathways consistent with target engagement. Covered by: prnewswire.com |
#2 AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS Published 2026-06-25 AFRRI and NIAID designed a proprietary PBI-BM2.5 protocol to evaluate Valion Bio’s entolimod for GI-ARS using validated animal models. Covered by: prnewswire.com |
#3 Two Claudin 18.2 ADCs Enter Final Stretch Of Global Race With China NDA Published 2026-06-25 Two anti-Claudin 18.2 antibody-drug conjugates are approaching potential world-first approvals in China, with final regulatory steps underway. Covered by: insights.citeline.com |
#4 Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data Published 2026-06-26 Artiva’s CEO says its NK cell–based, donor-derived cell therapy for autoimmune conditions is intended for community administration and potential re-dosing, with a 350-patient randomized rheumatoid arthritis trial planned to start this year. Covered by: biotechtv.com |
#5 Puerto Rico makes its case as a biotech manufacturing hub Published 2026-06-25 Puerto Rico is positioning itself as a biotech and advanced therapy manufacturing location, leveraging its existing pharmaceutical manufacturing experience to attract developers seeking scale and regulatory alignment. Covered by: fiercebiotech.com |
#6 Actio Biosciences has a precision medicine approach to rare diseases - promising preclinical data in a genetically defined epilepsy has them eagerly awaiting forthcoming clinical results Published 2026-06-26 Actio Biosciences’ CEO said limited access to medicines for rare genetic diseases drove its development efforts, and the company’s KCNT-1 program is in clinic after preclinical efficacy results. Covered by: biotechtv.com |
#7 CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand Published 2026-06-25 CStone Pharmaceuticals appointed Arrotex to handle registration, market access, and commercialization of sugemalimab in Australia and New Zealand under an exclusive agreement. Covered by: prnewswire.com |
#8 Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future Market Insights Published 2026-06-25 A study by Future Market Insights claims the global rare neurological disease treatment market will grow, citing increased orphan drug approvals and expanding genomic diagnostics. Covered by: prnewswire.com |
#9 How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery Published 2026-06-26 iBio says it reached a clinic after adopting an AI-powered discovery platform in 2022, and it describes the outcome as vindication. Covered by: fiercebiotech.com |
#10 Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy Published 2026-06-25 Fosun Pharma co-president Xinli Wang said the company used two recent deals to rapidly expand its Alzheimer’s disease portfolio and build independent U.S. capabilities. Covered by: fiercebiotech.com |
